Clinical Trials Logo

Filter by:
NCT ID: NCT06047964 Recruiting - Stroke Clinical Trials

Paclitaxel Drug-eluting Balloon Catheters in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis and Restenosis

Start date: March 23, 2023
Phase: N/A
Study type: Interventional

This study is aiming to evaluate the safety and efficacy of SeQuent® Please CIS in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis and restenosis after interventional therapy.

NCT ID: NCT06047860 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Start date: June 16, 2023
Phase: Phase 2
Study type: Interventional

Exploring the efficacy and safety of recombinant human vascular endothelial inhibitor (Endo) in combination with Bragg therapy in advanced refractory non-small cell lung

NCT ID: NCT06047574 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome

Start date: September 18, 2023
Phase:
Study type: Observational

The investigators collected clinical data and serum samples of patients with polycystic ovary syndrome (PCOS) in this study, used statistical software such as SPSS for date analysis, and used experimental techniques such as ELISA and flow cytometry to detect serum samples, aiming to explore the relationship between the body anthropometry, skin conditions, psychosomatic status, diet, sleep, exercise, glucose and lipid metabolism, gonadal hormones, and body fat distribution in patients with polycystic ovary syndrome, and to discovery new biomarkers. Multidisciplinary exploration of the mechanisms of disease occurrence and development, the establishment of a PCOS multicenter, multidisciplinary and multidimensional clinical research database, combined with the established statistical analysis strategy for big data and analysis, to promote the realization of more accurate personalized medicine.

NCT ID: NCT06047197 Recruiting - Clinical trials for Refractory Diffuse Large B-cell Lymphoma

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Start date: September 5, 2023
Phase: Phase 1
Study type: Interventional

This trial is a phase I clinical trial aimed at the safety and tolerability of RC19D2 cell injection in the treatment of CD19 positive patients with recurrent or refractory diffuse large B-cell lymphoma

NCT ID: NCT06047158 Recruiting - Stomach Neoplasms Clinical Trials

Effects of Omega-3 Fish Oil Fat Emulsion on Rehabilitation and Immune Function After Radical Surgery Combined With Intraperitoneal Hyperthermic Infusion Chemotherapy in Patients With Locally Advanced Gastric Cancer

Start date: December 1, 2022
Phase:
Study type: Observational

The purpose of this study was to investigate the effects of omega-3 fish oil fat emulsion on peripheral blood C-reactive protein, total lymphocyte count, plasma albumin and immune function after radical surgery combined with intraperitoneal hyperthermic perfusion chemotherapy in patients with locally advanced gastric cancer. at the same time, to explore the effects of omega-3 fish oil fat emulsion on complications, length of stay and total cost of hospitalization. The main question it aims to answer is whether the use of omega-3 fish oil fat emulsion can improve patients' immunity, speed up recovery and reduce costs. Participants will comprehensively collect patient-related baseline data, including sex, age, BMI, ASA grade, tumor location, histological grade, pathological tumor type, pTNM stage (AJCC cancer stage 8), and perilymphatic vascular / nerve infiltration. Immune function evaluation related index: peripheral blood lymphocyte count. Plasma albumin concentration, C-reactive protein, postoperative infectious complications, length of stay and cost of hospitalization. Finally, statistical analysis software was used to analyze the differences between the two groups, evaluate the above indicators and draw mutual conclusions.

NCT ID: NCT06047080 Recruiting - Clinical trials for Large B-Cell Lymphoma

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Start date: September 18, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).

NCT ID: NCT06046963 Recruiting - Gastric Cancer Clinical Trials

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion as First-line Treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with malignant ascites

NCT ID: NCT06046911 Recruiting - Postural Balance Clinical Trials

Effects of Tai Chi on Postural Balance and Quality of Life in the Elderly With Gait Disorder

Start date: September 8, 2023
Phase: N/A
Study type: Interventional

The goal of this intervention study was to test balance ability and quality of life in older adults with gait problems. The main questions it aims to answer are: 1. Can the balance ability of elderly people with gait disorders be improved through Tai Chi intervention? 2. Whether Tai Chi intervention can improve the quality of life of elderly people with gait disorders. Participants will be divided into an experimental group and a control group. The experimental group will undergo 12 weeks of Tai Chi intervention, while the control group will maintain daily habits, including simple walking or stretching activities.

NCT ID: NCT06046391 Recruiting - Clinical trials for Seasonal Allergic Rhinitis

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

Start date: July 6, 2023
Phase: Phase 2
Study type: Interventional

Allergic rhinitis (AR) affects large population worldwide, the most commonly used medication include anti-histamine, nasal spray and anti-LTRAs inhibitors (leukotriene receptor antagonists), Even after those first-line treatment, there is still a large number of patient (~20%) are not well/adequately controlled. Anti-IgE antibody has been approved to treat moderate to severe AR by PMDA/Japan in 2020, demonstrating the efficacy of IgE blockade in the treatment of allergic rhinitis. The current study presents a novel anti-IgE antibody (LP-003) with higher affinity to IgE, stronger efficacy and longer half-life.

NCT ID: NCT06046313 Recruiting - Clinical trials for Acute Myeloid Leukemia

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Start date: October 19, 2023
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.